Q32 Bio Inc.
corporate_fare Company Profile
Q32 Bio Inc. (NASDAQ:QTTB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for QTTB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-30, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for QTTB spans 8-K, 10-Q, 424B5, S-3.
Recent high-impact activity:
- Bempikibart Shows Durable Off-Drug Response in Phase 2a Alopecia Areata Trial
- Q32 Bio Reports Q2 2026 Results: $106.3M Cash, $187.6M Follow-On Financing, and Bempikibart Phase 3 Runway
- Q32 Bio Reports Q2 Results, Cash Runway Through Phase 3, and Plans for Bempikibart Registration Trial in 2027
- Q32 Bio Prices $200M Offering at $18.25, a 63% Premium to Pre-Data Price
- Q32 Bio Prices $200M Public Offering at $18.25/Share, Riding Positive Phase 2a Data
Financial Snapshot
Short Interest & Short Volume
12.13 days to coverFINRA reported short interest of 5,590,228 shares in QTTB as of the October 30, 2026 settlement, a 1.1% decrease from the prior period — about 12.1 days to cover at its recent average daily volume. On November 20, 2026, 65.0% of QTTB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for QTTB, detected from its recent SEC filings · based on capital-structure filings through 2026-07-15.
$200M Follow-On Priced at $18.25/Share · 63% Premium to Pre-Data Price
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →